BTX 1801

About Botanix Pharmaceuticals

Botanix Pharmaceuticals is a clinical-stage biotech focused on developing and commercializing novel dermatology and antimicrobial therapeutics. Its core achievement is the FDA approval and US launch of Sofdra™, a first-in-class topical anticholinergic for excessive underarm sweating, which is also approved in Japan and South Korea. The company's strategy leverages a dual-technology platform—Permetrex™ for enhanced skin delivery and synthetic CBD for its anti-inflammatory and antimicrobial properties—to address large, underserved markets. With a lean, US-focused commercial operation and an experienced leadership team, Botanix aims to transform its pipeline into a portfolio of high-value dermatology products.

Therapeutic Areas